Alexis实用战术主动型ETF LEXI 深 沪
等待开盘 11-13 09:30:00 美东时间
39.8417
-0.182
-0.46%
华盛通- 最 高40.05
- 今 开39.86
- 成交量 1.37万股
- 最 低 39.8417
- 昨 收 40.0239
- 总市值 2.01亿
- 52周最高 41.36
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 34.255
- 委 比 0.00%
- 总股本 504.68万
- 历史最高 41.36
- 量 比 1.12
- 振 幅 0.52%
- 历史最低 19.647
- 每 手 1
- 风险率 2.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kentucky Benefits from 19,000 New Kinetic Fiber Builds
Kinetic announced a major broadband expansion in Kentucky, delivering multi-gig fiber internet to 19,000 additional homes across more than 80 communities in Q3 2026. The expansion highlights Kinetic’s commitment to delivering better technology at a better value for customers. According to Ookla® Speedtest Intelligence® data, Kinetic delivers the fastest internet speeds in multiple Kentucky cities. In Q3, Kinetic added fiber locations in Lexington...
11-10 14:30
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
FDA has granted priority review for uniQure's BLA for AMT-130 (ifezuntirgene inilparvovec) in Huntington's disease, with a PDUFA target action date of May 1, 2027. The company has aligned with FDA on the confirmatory study design and expects to begin patient screening in the U.S. by end of 2026. uniQure reported $768.4 million in cash, cash equivalents, and investment securities as of September 30, 2026, expected to fund operations into 2030. Thi...
11-04 12:05
uniQure to Announce Third Quarter 2026 Financial Results
uniQure N.V. will report third quarter 2026 financial results on November 4, 2026, followed by a conference call at 8:30 a.m. ET. The event will be webcast on uniQure’s website, with a replay available for 90 days. Analysts can join the call by dialing (646) 307-1963 or (800) 715-9871 and entering conference ID 5075555. uniQure, a leader in gene therapy, has achieved historic milestones in treating hemophilia B and is advancing treatments for Hun...
10-28 11:05
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
Voyager Therapeutics announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston, November 16-19, 2026. The presentations will focus on VY1706, a gene therapy to lower tau production in the brain, and VY7523, a monoclonal antibody targeting tau's C-terminal region. Both studies are in early Alzheimer's disease. The posters will be available on Voyager's website.
10-27 12:01
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
Voyager Therapeutics announced that Robin Swartz, its Chief Business and Operating Officer, has been appointed President and will succeed Alfred W. Sandrock Jr. as CEO in Q1 2027. Sandrock will remain CEO until the release of initial acute safety data for VY1706 in early Alzheimer’s disease, then continue on the Board. Swartz, with extensive experience in biotech, will lead Voyager’s pipeline advancement.
10-21 12:01
FSI ANNOUNCES THIRD QUARTER 2026 REVENUE
Flexible Solutions International, Inc. (NYSE-AMERICAN: FSI) reported a 36% year-over-year increase in Q3 2026 revenue, rising to $14.35 million from $10.56 million in Q3 2025. The growth was attributed to full operations at the Panama factory, strong performance in the ENP division, and progress in food-grade production. Full financial results will be released on November 13, 2026, with a conference call scheduled for November 16, 2026.
10-19 13:00
Kinetic Expands Fiber Footprint in Lexington by More than 30%: Community Celebration to Come
Kinetic has expanded its fiber network in Lexington by 31% over the past year, adding 11,400 new fiber locations, benefiting nearly 47,000 households. The expansion supports remote work, gaming, streaming, agriculture, and telehealth. Kinetic is celebrating with free community events from Oct. 12-18, including tech courses, charity activities, and a movie night. Fiber networks boost business growth, home values, and sustainability, using 95% less...
10-12 13:30
